peptide
Survodutide
Weight lossalso known as BI 456906
An investigational dual GLP-1 / glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma.
Currently in Phase III trials for obesity and Phase II for metabolic dysfunction-associated steatohepatitis (MASH). Glucagon-receptor activation is studied for its direct effect on hepatic fat metabolism.
7 vendors with finnrick test grades. Higher grade = higher confirmed purity. Pricing data is pending for this peptide — grades below reflect independent purity testing.
| # | Vendor | Grade | Score | Tests | Reputation |
|---|---|---|---|---|---|
| 1 | Great | A | 8.3 | 3 | 73 |
| 2 | Peptide-Sflag Great | A | 7.5 | 4 | 72 |
| 3 | Great | A | 7.2 | 3 | 71 |
| 4 | Polaris Peptideslogin required Good | B | 7.3 | 5 | 73 |
| 5 | Good | B | 6.8 | 4 | 72 |
| 6 | Okay | C | 5.2 | 3 | 67 |
| 7 | Utherflag Poor | D | 7.2 | 4 | 74 |
Grades sourced from finnrick.com. Grade A = highest confidence in purity based on independent lab testing. Score is averaged across 26 individual tests.